Drugs in MeSH Category Adrenergic Agents

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Epic Pharma Llc	BENZPHETAMINE HYDROCHLORIDE	benzphetamine hydrochloride	TABLET;ORAL	090346-001	Dec 15, 2015	AA	RX	No	No
Amneal	EPHEDRINE SULFATE	ephedrine sulfate	SOLUTION;INTRAVENOUS	212932-001	Oct 23, 2019	AP	RX	No	No
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-002	Jan 27, 2016	AB	RX	Yes	No	9,017,731		Y
Teva	METHAMPHETAMINE HYDROCHLORIDE	methamphetamine hydrochloride	TABLET;ORAL	086359-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Neos Theraps	ADZENYS XR-ODT	amphetamine	TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL	204326-004	Jan 27, 2016	AB	RX	Yes	No	8,840,924		Y

Market Dynamics and Patent Landscape for Drugs in NLM MeSH Class: Adrenergic Agents

Last updated: April 25, 2026

What does the “Adrenergic Agents” segment look like commercially?

The MeSH category “Adrenergic Agents” (NLM) covers drugs that act on adrenergic receptors and related pathways, including alpha- and beta-adrenergic agonists and antagonists, and adrenergic receptor-targeted therapies used across cardiovascular, respiratory, ophthalmic, and acute care settings. This breadth drives a market structure where the top revenue pools tend to cluster around (1) long-established branded agents with late-lifecycle line extensions and (2) high-impact niche acute-care products with constrained competitors.

Demand drivers by use-case (typical in the adrenergic class):

• Cardiovascular: beta-blockers, alpha-blockers, and related agents used in chronic disease management and acute hemodynamic control.
• Respiratory: beta-agonists (and some adrenergic-pattern bronchodilators) for obstructive lung disease.
• Ophthalmic: adrenergic agonists used for glaucoma and intraocular pressure control.
• Acute/emergency care: rapid-acting alpha agonists used for hypotension, shock protocols, and perioperative indications.

Pricing and access dynamics:

• Large parts of the class include off-patent generics in major countries, which compresses pricing and shifts competitive pressure to manufacturing cost, formulary position, and channel access.
• Commercial differentiation increasingly concentrates in delivery system reformulations (extended-release oral, inhalation device/particle engineering, ophthalmic formulations) and label expansion rather than new receptor targets.
• Uptake is often guideline-driven (hospital formularies for acute agents; chronic disease algorithms for beta-blockers) which raises the bar for clinical differentiation in late-stage filings.

Investment implication: In adrenergic agents, pipeline value tends to skew toward (a) new combinations or delivery innovations with clear clinical endpoints, (b) next-generation inhalation/ocular platforms, and (c) improved safety/administration in acute care rather than entirely new pharmacology.

---

How does the patent landscape typically evolve in adrenergic agents?

Adrenergic agents follow a mature IP lifecycle pattern:

1. Core composition-of-matter patents for landmark molecules generally expire.
2. Post-expiry protection shifts to secondary patents:
   • Formulations (salt forms, polymorphs, stabilized compositions)
   • Methods of use (new dose regimens, new indications, responder subgroups)
   • Device and delivery systems (inhaler technology, ophthalmic delivery systems)
   • Process patents (manufacturing route improvements)
3. The strongest “evergreening” tends to cluster around route-specific or device-specific claims, because these can survive core expiry when the commercial product continues to rely on a differentiated manufacturing or delivery method.

Where enforcement concentrates:

• Generics often enter with bioequivalent generic API, then seek a clearance path around secondary patents by adjusting formulation or delivery approach.
• Patents tied to delivery systems and specific method-of-use regimens create the longest runway for branded product differentiation, because they require closer claim mapping to substitute products.

---

What are the main competitive dynamics across adrenergic subsegments?

Beta-agonists (respiratory)

• Competitive pressure is dominated by device + formulation rather than mechanism alone.
• Patents tend to cover:
  • controlled release mechanisms
  • specific suspension/particle engineering for inhalation
  • device-integrated dosing protocols

Commercial dynamic: brand retention often depends on maintaining formulary access for inhalation products with differentiated device performance and patient adherence.

Alpha-adrenergic agents (acute care and ophthalmic niches)

• Strong emphasis on rapid onset and tolerability.
• IP often protects:
  • specific dosing regimens
  • routes and compositions tailored for hospital protocols
  • ocular formulations with controlled residence time

Commercial dynamic: hospital pathway adoption and guideline alignment are decisive; payer-driven substitution can be slower when administration workflow is entrenched.

Beta-blockers and alpha-blockers (cardiovascular)

• Many products are off-patent; differentiation comes from:
  • extended-release versions
  • fixed-dose combinations
  • use in narrower patient subsets (label expansions)
• Patent activity often clusters around dose and schedule rather than new molecules.

Commercial dynamic: competition becomes “switch cost” driven: prescribers stick to stable therapy unless there is compelling safety or efficacy switching evidence.

---

What is the enforceable patent landscape today for adrenergic agents?

A precise, drug-by-drug landscape requires that each MeSH member substance be mapped to:

• jurisdiction-specific filings,
• grant status,
• remaining term by patent family,
• and claim scope by product formulation and method-of-use.

No complete list of included substances or a corresponding set of active patent families is provided in the input. Without that mapping, generating a complete enforcement-term table would risk mixing unrelated molecules or mis-allocating term/expiry.

What can be stated reliably from the definitional scope is that the adrenergic class is structurally consistent with an offspring pattern of secondary IP around formulation, method-of-use, and delivery systems, because the class contains many mature compounds and route-specific products.

Actionable market read-through (without individual family IDs):

• Expect short-to-mid residual value in mainstream APIs, with longer value tailing in inhalation/ocular formulations and protocolized dosing regimens.
• Expect litigation risk where secondary patents claim features that are integral to the branded product’s delivery or regimen, because generic entrants can be blocked unless design-arounds avoid claim coverage.

---

Where do new patent opportunities concentrate (R&D angle)?

For adrenergic agents, commercially durable innovation tends to be located in three zones:

1. Delivery system IP

   • inhalation device engineering
   • ocular formulation residence-time control
   • controlled-release oral platforms

2. Regimen and indication specificity

   • narrower indications with defined populations
   • improved titration or maintenance schedules
   • combination regimens with aligned endpoints

3. Safety/tolerability-driven patient stratification

   • subgroup targeting backed by endpoints
   • reduced adverse event profiles (dose mapping and exposure control)

Market dynamic: These zones map onto the way formularies and care pathways evaluate alternatives.

---

How should commercial teams model revenue risk from patent cliffs in this class?

A practical approach for adrenergic agents uses a split model:

• API IP horizon: composition-of-matter expiry sets the generic entry timing for the API.
• Product IP horizon: secondary patents for formulation/delivery/method-of-use set the time until true therapeutic substitution becomes price-competitive.

Revenue risk logic:

• If the product’s market share relies mainly on API equivalence, the cliff is closer to core expiry.
• If share relies on delivery performance, workflow integration, or regimen-specific advantages, the cliff shifts out.

---

Key takeaways

• Adrenergic Agents is a broad, mature class where competition shifts from molecular novelty to formulation, delivery, and regimen-specific IP.
• Commercial performance is typically guideline- and workflow-driven, making secondary patents central to post-core-expiry brand retention.
• For market forecasting and investment triage, revenue risk must be modeled with two horizons: API expiry and product-level secondary IP tied to the branded formulation and administration pathway.
• Patent landscape value tends to concentrate where substitution is harder without changing the delivery system or method-of-use, especially in respiratory inhalation and ophthalmic products.

---

FAQs

1) Is the adrenergic agents MeSH category focused on receptor agonists only?

No. It covers adrenergic agonists and antagonists, spanning multiple receptor types and therapeutic use areas.

2) Why do secondary patents matter more in adrenergic agents than new composition patents?

Because many flagship adrenergic molecules are mature. Brand differentiation and enforcement often persist through formulation, regimen, and delivery system claims.

3) What subsegments tend to have the strongest device or delivery-related IP?

Respiratory (inhalation) and ophthalmic formulations are the most common places where delivery differentiation is claimable and substitution is slower.

4) How should investors think about generic entry timing in this class?

Generic entry timing aligns first with core API patent expiry, then extends or compresses based on whether secondary patents block or tolerate substitution in the actual product form used in care settings.

5) What is the most common pathway for branded line extensions in adrenergic agents?

New or expanded method-of-use/regimen and product formulation/delivery improvements that preserve enforceable claims after core expiry.

---

References

[1] National Library of Medicine (NLM). MeSH Browser. “Adrenergic Agents.” https://www.ncbi.nlm.nih.gov/mesh/